Last reviewed · How we verify
NCT03574558
Personalized Automated Determination of Insulin Pump Setting for Subjects With Type 1 Diabetes Switching From MDI to Pump Therapy and Vice Versa- Safety and Efficacy Feasibility Study
NA trial testing MD-Logic Switch Advisor in Type1diabetes in 28 participants. Completed in 25 November 2019.
25 November 2019
Quick facts
| Lead sponsor | Rabin Medical Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 28 |
| Start date | 1 August 2018 |
| Primary completion | 25 November 2019 |
| Estimated completion | 25 November 2019 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- MD-Logic Switch Advisor
Conditions studied
- Type1diabetes — all drugs for Type1diabetes →
Sponsor
Rabin Medical Center
Who can join
Adults 6 to 30, any sex, with Type1diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The "MD-Logic Switch Advisor" is a software product that is designed to assist in insulin dosage decision making and has two components: A. MD-Logic Switch Advisor for initiation of pump therapy - this product is designed to assist physicians in decision making when initiating insulin pump therapy. B. MD-Logic Switch Advisor for patients who use insulin pump therapy and need to switch to MDI (Multiple Daily Injections). This feasibility study will be divided to two parts: part A - will include up to 20 patients to evaluate in a feasibility study the switch Advisor from MDI to pump therapy part B - will include up to 20 patients to evaluate in a feasibility study the switch Advisor from pump therapy to MDI The main objective is to evaluate the safety and efficacy of using the MD-Logic Switch Advisor to determine insulin dosing for subjects with type 1 diabetes using pump therapy who wish to switch to from pump to MDI therapy and vice versa.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03574558
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type1diabetes
Currently open trials in the same condition.
- NCT07139808 — Safety and Effectiveness of A Novel Continuous Glucose and Ketone Monitoring System · NA · recruiting
- NCT07092761 — Evaluation of the Accuracy and Safety of A Novel Real-Time Continuous Glucose Monitoring System · NA · recruiting
- NCT06646107 — Adherence to Mediterranean Diet in Type 1 Diabetes Initiating Minimed 780G: Glucose Metrics vs Insulin Metrics, is There · recruiting
- NCT06753994 — Continuous Ketone Monitoring in People With Type 1 Diabetes Using SGLT2 Inhibitors · Phase 1 · recruiting
- NCT05668507 — REACHOUT Mental Health Support Mobile App · NA · active not recruiting
Other Rabin Medical Center trials
Trials by the same sponsor.
- NCT06837909 — Transversus Abdominis Plane Block Versus Wound Infiltration for Pulmonary Function Preservation Following Laparoscopic L · NA · recruiting
- NCT06951399 — Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT07208240 — Tb-PSMA-I&T Radionuclide Before Radical Prostatectomy in Patients With Locally Advanced Prostate Cancer - TbeforePROST T · Phase 1, PHASE2 · recruiting
- NCT06931119 — Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients · Phase 1 · not yet recruiting
- NCT06966427 — Prospective Evaluation of a Dose Guidance System for People With Diabetes Initiating Basal Insulin or Using Insulin Inje · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03574558 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rabin Medical Center
- Last refreshed: 27 December 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03574558.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing